XL-001 / Allogenica - LARVOL DELTA

Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership (GlobeNewswire) - "Allogenica...has been awarded a €2.5 million grant under the French government’s 'Innovations in Biotherapies and Bioproduction for France 2030' program....Allogenica overcomes these limitations with its universal CAR-T therapy, XL-001, which targets CD19-positive blood cancers....This funding will enable Allogenica to accelerate the development of XL-001, moving it from preclinical research to clinical application....Allogenica aims to initiate Phase I clinical trials by 2027, positioning XL-001 as a leading CAR-T therapy for CD19-positive malignancies....Next pipeline developments include XL-002, a first-in-class armed CAR-pre-T therapy for leukemia, and XL-003, a novel engineered pre-T therapy for solid tumors, expanding Allogenica's commitment to address a broad range of cancers."

Financing • New P1 trial • Hematological Malignancies • Leukemia • Solid Tumor